MGNX
MACROGENICS INC
Overview
MacroGenics develops antibody-based cancer therapeutics using proprietary platforms including bispecific DART and TRIDENT molecules and antibody-drug conjugates (ADCs).
MACROGENICS INC is a Healthcare company operating in Biotechnology with a $291.1M market cap.
MGNX missed consensus EPS by 0.1% in Q1 FY2026, reported May 13, 2026.
15 earnings calls indexed on Spoken Alpha.
Behavioral analysis
Management language signature
Disclosures
Investor Relations
Transcripts
Recent earnings calls
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
- Q4 FY2024Earnings2025-03-2020 Q&A exchanges
- Q2 FY2024Earnings2024-11-0520 Q&A exchanges
- Q1 FY2024Earnings2024-05-0925 Q&A exchanges
- Q4 FY2023Earnings2024-03-0729 Q&A exchanges
- Q3 FY2023Earnings2023-11-0732 Q&A exchanges
- Q2 FY2023Earnings2023-08-0927 Q&A exchanges
- Q1 FY2023Earnings2023-05-0913 Q&A exchanges
- Q4 FY2022Earnings2023-03-1524 Q&A exchanges
- Q3 FY2022Earnings2022-11-0511 Q&A exchanges
- Q2 FY2022Earnings2022-08-0812 Q&A exchanges
- Q1 FY2022Earnings2022-05-0325 Q&A exchanges
- Q4 FY2021Earnings2022-02-2431 Q&A exchanges
- Q3 FY2021Earnings2021-11-0315 Q&A exchanges
- Q2 FY2021Earnings2021-07-3025 Q&A exchanges
- Q1 FY2021Earnings2021-04-2924 Q&A exchanges
History
Earnings history
- Q1 FY20262026-05-13EPS$-0.58 vs $-0.55-5.9%Rev$20.8M vs ——EODHD
- Q4 FY20252026-02-18EPS$-0.22 vs $-0.27+18.4%Rev$41.2M vs ——EODHD
- Q3 FY20252025-11-11EPS$0.27 vs $-0.41+100.0%Rev$72.8M vs ——EODHD
- Q2 FY20252025-08-13EPS$-0.57 vs $-0.46-23.9%Rev$22.2M vs ——EODHD
- Q1 FY20252025-05-06EPS$-0.65 vs $-0.69+5.8%Rev$13.2M vs ——EODHD
- Q4 FY20242025-03-04EPS$-0.82 vs $-0.59-38.6%Rev$17.7M vs ——EODHD
- Q2 FY20242024-11-04EPS$0.90 vs $0.21+100.0%Rev$110.7M vs ——EODHD
- Q1 FY20242024-05-08EPS$-0.84 vs $-0.64-31.3%Rev$9.1M vs ——EODHD
- Q4 FY20232024-03-06EPS$-0.75 vs $-0.15-100.0%Rev$10.7M vs ——EODHD
- Q3 FY20232023-11-05EPS$0.28 vs $-0.10+100.0%Rev$10.4M vs ——EODHD
- Q2 FY20232023-08-08EPS$-0.69 vs $-0.52-32.7%Rev$13.1M vs ——EODHD
- Q1 FY20232023-05-08EPS$-0.61 vs $0.45-100.0%Rev$24.5M vs ——EODHD
- Q4 FY20222023-03-14EPS$0.21 vs $0.10+100.0%Rev$73.1M vs ——EODHD
- Q3 FY20222022-11-02EPS$-0.40 vs $-0.38-5.3%Rev$41.7M vs ——EODHD
- Q2 FY20222022-08-07EPS$-0.67 vs $-0.97+30.9%Rev$26.0M vs ——EODHD
- Q1 FY20222022-05-02EPS$-1.08 vs $-0.86-25.6%Rev$10.7M vs ——EODHD
- Q4 FY20212022-02-23EPS$-0.95 vs $-0.81-17.3%Rev$14.1M vs ——EODHD
- Q3 FY20212021-11-01EPS$-0.86 vs $-0.69-24.6%Rev$15.7M vs ——EODHD
- Q2 FY20212021-07-28EPS$-0.66 vs $-0.46-43.5%Rev$30.8M vs ——EODHD
- Q1 FY20212021-04-28EPS$-0.90 vs $-0.61-47.5%Rev$16.9M vs ——EODHD
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q1 FY2026 | 2026-05-13 | $-0.58 | $-0.55 | -5.9% | $20.8M | — | — | EODHD |
| Q4 FY2025 | 2026-02-18 | $-0.22 | $-0.27 | +18.4% | $41.2M | — | — | EODHD |
| Q3 FY2025 | 2025-11-11 | $0.27 | $-0.41 | +100.0% | $72.8M | — | — | EODHD |
| Q2 FY2025 | 2025-08-13 | $-0.57 | $-0.46 | -23.9% | $22.2M | — | — | EODHD |
| Q1 FY2025 | 2025-05-06 | $-0.65 | $-0.69 | +5.8% | $13.2M | — | — | EODHD |
| Q4 FY2024 | 2025-03-04 | $-0.82 | $-0.59 | -38.6% | $17.7M | — | — | EODHD |
| Q2 FY2024 | 2024-11-04 | $0.90 | $0.21 | +100.0% | $110.7M | — | — | EODHD |
| Q1 FY2024 | 2024-05-08 | $-0.84 | $-0.64 | -31.3% | $9.1M | — | — | EODHD |
| Q4 FY2023 | 2024-03-06 | $-0.75 | $-0.15 | -100.0% | $10.7M | — | — | EODHD |
| Q3 FY2023 | 2023-11-05 | $0.28 | $-0.10 | +100.0% | $10.4M | — | — | EODHD |
| Q2 FY2023 | 2023-08-08 | $-0.69 | $-0.52 | -32.7% | $13.1M | — | — | EODHD |
| Q1 FY2023 | 2023-05-08 | $-0.61 | $0.45 | -100.0% | $24.5M | — | — | EODHD |
| Q4 FY2022 | 2023-03-14 | $0.21 | $0.10 | +100.0% | $73.1M | — | — | EODHD |
| Q3 FY2022 | 2022-11-02 | $-0.40 | $-0.38 | -5.3% | $41.7M | — | — | EODHD |
| Q2 FY2022 | 2022-08-07 | $-0.67 | $-0.97 | +30.9% | $26.0M | — | — | EODHD |
| Q1 FY2022 | 2022-05-02 | $-1.08 | $-0.86 | -25.6% | $10.7M | — | — | EODHD |
| Q4 FY2021 | 2022-02-23 | $-0.95 | $-0.81 | -17.3% | $14.1M | — | — | EODHD |
| Q3 FY2021 | 2021-11-01 | $-0.86 | $-0.69 | -24.6% | $15.7M | — | — | EODHD |
| Q2 FY2021 | 2021-07-28 | $-0.66 | $-0.46 | -43.5% | $30.8M | — | — | EODHD |
| Q1 FY2021 | 2021-04-28 | $-0.90 | $-0.61 | -47.5% | $16.9M | — | — | EODHD |
Source: EODHD. MGNX reported actuals as published; sparse fields render as —.
Track Record
SampleSpoken Alpha tracks MGNX's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.
Beats consensus 10/10 quarters but stock falls 100% of the time
SampleWhen a company consistently beats but the stock doesn't react, consensus is usually set too low or the buy-side number is materially above sell-side. Watch for guidance walk-downs ahead of the print.
Raised guidance 3 quarters in a row
SampleConsecutive raises tighten the bar quarter over quarter. Watch the most recent print for the magnitude of the beat — a smaller beat against a higher bar is the early signal that the regime is breaking.
Quarterly beats & misses
Sample| Quarter | Actual EPS | Consensus | Surprise | 1D | 5D |
|---|---|---|---|---|---|
| Q1 FY2024 | $1.44 | $1.26 | +13.9% | -9.8% | -12.5% |
| Q4 FY2024 | $1.46 | $1.33 | +9.8% | -1.4% | +0.4% |
| Q3 FY2024 | $1.36 | $1.25 | +8.5% | -3.3% | -4.8% |
| Q2 FY2024 | $1.43 | $1.43 | -0.1% | -4.8% | -6.5% |
| Q1 FY2023 | $1.57 | $1.39 | +12.7% | -3.2% | -3.6% |
| Q4 FY2023 | $1.57 | $1.38 | +14.0% | -9.7% | -12.7% |
| Q3 FY2023 | $1.27 | $1.27 | +0.1% | -2.9% | -5.7% |
| Q2 FY2023 | $1.42 | $1.32 | +7.6% | -0.6% | -3.3% |
| Q1 FY2022 | $1.68 | $1.59 | +5.7% | -8.1% | -7.7% |
| Q4 FY2022 | $1.48 | $1.31 | +12.6% | -8.7% | -10.9% |
Guidance change history
Sample- Q1 FY2024Raised2024-04-15
- Q4 FY2024Raised2024-13-15
- Q3 FY2024Raised2024-10-15
- Q2 FY2024Maintained2024-07-15
- Q1 FY2023Raised2023-04-15
- Q4 FY2023Raised2023-13-15
- Q3 FY2023Maintained2023-10-15
- Q2 FY2023Raised2023-07-15
Top executives
SampleSpoken Alpha builds an accountability record per executive — how the person's own guidance, language, and reactions have evolved across every call they've appeared on. The one-liners below are illustrative placeholder data pending the deviation v1 work. Click any name for the full role timeline and call appearance history.
- Eric Blasius RisserCEO10 mono recorded callsCurrentSample
CEO since 2025 • 1/2 beats (50%) • last guidance cut Q3 FY2024
- James KarrelsCFO4 mo15 callsCurrentSample
CFO since 2026 • 2/2 beats (100%) • last guidance cut Q2 FY2024
- Ezio BonviniSr VP, Research & CSO1 yr 4 mono recorded callsCurrentSample
OTHER_C_SUITE since 2025 • 1/2 beats (50%) • last call held guidance Q3 FY2024
- Jeffrey Stuart PetersSenior VP, GC, and Secretary4 mono recorded callsCurrentSample
OTHER since 2026 • 1/2 beats (50%) • last guidance cut Q2 FY2024
- Beth Ann SmithVP, Controller & Treasurer1 yr 4 mono recorded callsCurrentSample
OTHER since 2025 • 2/2 beats (100%) • guidance suspended Q1 FY2024
- Thomas SpitznagelSr VP, Technical Ops1 yr 4 mono recorded callsCurrentSample
OTHER since 2025 • 1/2 beats (50%) • guidance suspended Q2 FY2024
Peers
Other companies in Healthcare
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
For developers and AI agents
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for MGNX.
$ curl https://api.spokenalpha.com/v1/companies/MGNXFAQ
Frequently asked about MGNX
Where can I find MACROGENICS INC's (MGNX) earnings call transcripts?
Spoken Alpha indexes MGNX's earnings call transcripts at https://spokenalpha.com/companies/MGNX. Each call links to attributed speakers and parsed analyst Q&A.
When was MACROGENICS INC's most recent earnings call?
MACROGENICS INC (MGNX) held its most recent earnings call on 2025-03-20, covering fiscal Q4 2024.
What sector is MGNX in?
MACROGENICS INC (MGNX) operates in the Healthcare sector (Biotechnology industry).